Brookfield resumes Grifols takeover talks for €7 billion - report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Source: SeekingAlpha
Brookfield's Takeover Talks: Canadian investment fund Brookfield has resumed discussions for a potential €7 billion takeover of Spanish pharmaceuticals company Grifols, following a previous offer that was rejected four months ago.
Grifols Stock Reaction: Following the news of the renewed talks, Grifols' stock price increased by 12% to €9.10 on the Spanish stock exchange.
Analyst Views on GRFS
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
